NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









DMC Biotechnologies

DMC Biotechnologies

Private
Morrisville, North CarolinaEnergy & Sustainabilityhttps://dmcbio.com/

Last Round

Series B

Jan 31, 2022

Total Funding Raised

$54.3M

Company Overview

DMC Biotechnologies is a biotechnology company that develops bio-based specialty chemicals and ingredients using a proprietary precision fermentation technology platform.

Sector

Energy & Sustainability

Verticals

Biotechnology, Clean Manufacturing, Sustainable Materials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

precision fermentationsynthetic biologybio-based chemicalsmetabolic engineeringfermented inositolsbiomanufacturingsustainable manufacturingbiotechtechnoeconomic analysisTEAjoint development agreementJDAindustrial biotechgreen chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DMC Biotechnologies Comparables

Compare DMC Biotechnologies with similar companies based on industry and business-model similarity.

DMC Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lygos
87%
ZymoChem
86%
Manus Bio
83%

DMC Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 31, 2022
Series ADec 16, 2019
GrantNov 18, 2019
SeedOct 8, 2018
SeedJan 9, 2018

Key People

Founding team and executive leadership

Jim Flatt

Chief Executive Officer

Executive Team

Ernesto Simon Vecilla

Chief Technology Officer

Executive Team

Kenny Erdoes

Chief Operating Officer

Executive Team

DMC Biotechnologies Investors

Notable investors and investment history

DMC Biotechnologies investors
InvestorRounds
Capricorn PartnersSeries A, Series B, Seed
Conti VenturesSeries B
Breakthrough Energy VenturesSeries A, Series B, Seed
Sofinnova PartnersSeries B, Series A
Boulder VenturesSeries A, Series B
Syensqo VenturesSeries B
Continental Grain CompanySeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2025

    K'Lynne Johnson appointed Chair of the Board of Directors.

  • Jan 14, 2025

    Dr. James (Jim) Flatt appointed as new Chief Executive Officer.

DMC Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DMC Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DMC Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersMorrisville, North Carolina
Employee Range41
Year Founded2014
Last FundingJan 31, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.